Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR070803 Combo vs Nab-paclitaxel/Gemcitabine in Advanced Pancreatic Cancer
NCT05751850Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of CPO-120 in pancreatic cancer (PC) (2 arms), sponsored by Hengrui. Primary endpoint: Overall Survival. Started Jun 2023; status: recruiting.
02
Drugs
CPO-120
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05751850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751850.